SAN DIEGO, Nov. 25, 2014 /PRNewswire/ -- Aethlon
Medical, Inc. (NASDAQ:OTCQB:AEMD), the pioneer in developing
targeted therapeutic devices to address infectious disease and
cancer, disclosed today that an Ebola patient who received
Hemopurifier® therapy has been reported to have been discharged
from Frankfurt University Hospital in Germany. The patient
was a Ugandan physician, who became infected with Ebola in
Sierra Leone where he was treating
other Ebola patients.
The Aethlon Hemopurifier® is a first-in-class bio-filtration
device that targets the rapid elimination of viruses and
immunosuppressive proteins from the circulatory system of infected
individuals. At the time Hemopurifier® therapy was
administered to the Ugandan physician, he was unconscious and
suffered from multiple organ failure. His viral load prior to
the administration of a single 6.5-hour Hemopurifier® treatment was
measured at 400,000 virus copies per milliliter of blood
(copies/ml). Post-treatment viral load was measured at 1,000
copies/ml and never again rose above that level. Viral load became
undetectable five days after therapy. The treatment was well
tolerated with no adverse events reported. Additionally, a
post-treatment elution protocol verified that 242 million Ebola
viruses were captured within the Hemopurifier® during
treatment.
In the United States,
Hemopurifier® therapy is available to treat Ebola patients through
FDA expanded access "emergency use" provisions to address life
threatening circumstances for which an alternative therapy is not
available. At present, no antiviral therapy or vaccine has proven
to be effective against Ebola virus infection in humans.
Aethlon will soon begin the first U.S. clinical Hemopurifier®
studies following the United States Food and Drug Administration's
(FDA)'s approval of an Investigational Device Exemption (IDE). The
study will contribute safety data to advance the device as a
broad-spectrum countermeasure against bioterror and pandemic
threats, including Ebola and chronic viral pathogens such as HIV
and Hepatitis C (HCV).
About Aethlon Medical, Inc.
Aethlon Medical creates targeted therapeutic devices to address
infectious disease, cancer and neurodegenerative
disorders. The company's lead product is the Aethlon
Hemopurifier®, a first-in-class device that selectively
targets the rapid elimination of circulating viruses and
tumor-secreted exosomes that promote cancer progression.
Exosome Sciences, Inc. is a majority owned subsidiary that is
advancing exosome-based products to diagnose and monitor cancer,
infectious disease and neurological disorders. For more
information, please visit http://www.aethlonmedical.com/ and
connect with the Company on Twitter, LinkedIn, Facebook and
Google+.
Certain statements herein may be forward-looking and involve
risks and uncertainties. Such forward-looking statements
involve assumptions, known and unknown risks, uncertainties and
other factors which may cause the actual results, performance or
achievements of Aethlon Medical, Inc. to be materially different
from any future results, performance, or achievements expressed or
implied by the forward-looking statements. Such potential risks and
uncertainties include, without limitation, that the ESI will not be
able to commercialize its future products, that the FDA will not
approve the initiation of the Company's clinical programs or
provide market clearance of the company's products, future human
studies whether revenue or non-revenue generating of the Aethlon
ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to
improve patient responsiveness to established cancer or hepatitis C
therapies or as a standalone cancer or hepatitis C therapy or as a
broad spectrum defense against viral pathogens, including ebola,
the Company's ability to raise capital when needed, the Company's
ability to complete the development of its planned products, the
Company's ability to manufacture its products either internally or
through outside companies and provide its services, the impact of
government regulations, patent protection on the Company's
proprietary technology, the ability of the Company to meet the
milestones contemplated in the DARPA contract, product liability
exposure, uncertainty of market acceptance, competition,
technological change, and other risk factors. In such instances,
actual results could differ materially as a result of a variety of
factors, including the risks associated with the effect of changing
economic conditions and other risk factors detailed in the
Company's Securities and Exchange Commission filings. The Company
undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events, or otherwise.
Contacts:
Leah-Michelle Nebbia (for
interviews requests)
Golin
202-585-2651
lnebbia@golin.com
James A. Joyce
Chairman and CEO
(Office) 858.459.7800 x301
(Cell) 619-368-2000
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Photo -
http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/ebola-patient-who-received-aethlon-hemopurifier-therapy-has-been-discharged-from-hospital-300000853.html
SOURCE Aethlon Medical, Inc.